NO309272B1 - Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene - Google Patents
Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene Download PDFInfo
- Publication number
- NO309272B1 NO309272B1 NO961160A NO961160A NO309272B1 NO 309272 B1 NO309272 B1 NO 309272B1 NO 961160 A NO961160 A NO 961160A NO 961160 A NO961160 A NO 961160A NO 309272 B1 NO309272 B1 NO 309272B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- benzyl
- compound
- trifluoromethyl
- bis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 399
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000000543 intermediate Substances 0.000 title description 4
- 150000001923 cyclic compounds Chemical class 0.000 title description 2
- -1 piperazino group Chemical group 0.000 claims description 169
- 150000003839 salts Chemical class 0.000 claims description 64
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 43
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 25
- 230000003042 antagnostic effect Effects 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 102000007124 Tachykinin Receptors Human genes 0.000 claims description 12
- 108010072901 Tachykinin Receptors Proteins 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 230000027939 micturition Effects 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims description 4
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- GKOXUINHRLDHBI-INIZCTEOSA-N (9s)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-phenyl-9,10-dihydro-8h-[1,4]diazepino[2,1-g][1,7]naphthyridine-6,12-dione Chemical group C([C@@H](CN1C(=O)C2=NC=CC=C2C(C=2C=CC=CC=2)=C1C1=O)C)N1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GKOXUINHRLDHBI-INIZCTEOSA-N 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- PJBUKQBYUYWWMO-KRWDZBQOSA-N (9s)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-9,10-dihydro-8h-[1,4]diazepino[2,1-g][1,7]naphthyridine-6,12-dione Chemical compound C([C@@H](CN1C(=O)C2=NC=CC=C2C(C=2C=CC(C)=CC=2)=C1C1=O)C)N1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PJBUKQBYUYWWMO-KRWDZBQOSA-N 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 429
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 152
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 151
- 239000013078 crystal Substances 0.000 description 112
- 239000002904 solvent Substances 0.000 description 111
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 100
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 77
- 238000004821 distillation Methods 0.000 description 77
- 239000000203 mixture Substances 0.000 description 77
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 50
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 48
- 238000000921 elemental analysis Methods 0.000 description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 239000000284 extract Substances 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- 102100024304 Protachykinin-1 Human genes 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 239000002585 base Substances 0.000 description 23
- 238000010992 reflux Methods 0.000 description 23
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 101800003906 Substance P Proteins 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000001228 spectrum Methods 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- WXLCDTBTIVJDCE-UHFFFAOYSA-N 1,4-oxazepine Chemical compound O1C=CC=NC=C1 WXLCDTBTIVJDCE-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- 238000010626 work up procedure Methods 0.000 description 13
- 101800000399 Neurokinin A Proteins 0.000 description 12
- 102400000097 Neurokinin A Human genes 0.000 description 12
- 239000002168 alkylating agent Substances 0.000 description 12
- 229940100198 alkylating agent Drugs 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 150000002430 hydrocarbons Chemical group 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- 150000002170 ethers Chemical class 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 238000006722 reduction reaction Methods 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 10
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 8
- HVBPRVTXOVIONS-UHFFFAOYSA-N 2-chloro-4-phenylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=C(Cl)N=CC=C1C1=CC=CC=C1 HVBPRVTXOVIONS-UHFFFAOYSA-N 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- OZRQNONLIIJJLJ-UHFFFAOYSA-N 2-[[3,5-bis(trifluoromethyl)phenyl]methylamino]ethanol Chemical compound OCCNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OZRQNONLIIJJLJ-UHFFFAOYSA-N 0.000 description 7
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 7
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 235000011054 acetic acid Nutrition 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 239000001045 blue dye Substances 0.000 description 7
- 235000017663 capsaicin Nutrition 0.000 description 7
- 229960002504 capsaicin Drugs 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229960003699 evans blue Drugs 0.000 description 7
- 150000008282 halocarbons Chemical class 0.000 description 7
- 229930195733 hydrocarbon Natural products 0.000 description 7
- 239000011630 iodine Chemical group 0.000 description 7
- 229910052740 iodine Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 150000007530 organic bases Chemical class 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- DUAXLVGFFDFSAG-RXMQYKEDSA-N (2r)-4-amino-2-methylbutan-1-ol Chemical compound OC[C@H](C)CCN DUAXLVGFFDFSAG-RXMQYKEDSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- KFJGEMXOMQHLBZ-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-8-carboxylic acid Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(C(=O)O)=CC=2C1=CC=CC=C1 KFJGEMXOMQHLBZ-UHFFFAOYSA-N 0.000 description 6
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 6
- 206010015866 Extravasation Diseases 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000036251 extravasation Effects 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- ADEXTNXECYSAKO-UHFFFAOYSA-N 3-(4-methylbenzoyl)pyridine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=CN=C1C(O)=O ADEXTNXECYSAKO-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- 108090000189 Neuropeptides Proteins 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 5
- 206010046543 Urinary incontinence Diseases 0.000 description 5
- LZBREHUQKVNPDK-UHFFFAOYSA-N [4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-8-yl]methyl acetate Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(COC(=O)C)=CC=2C1=CC=CC=C1 LZBREHUQKVNPDK-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- QAPGCKSLMOYEGM-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(2-hydroxyethyl)-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCO)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QAPGCKSLMOYEGM-UHFFFAOYSA-N 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 4
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DHVHORCFFOSRBP-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DHVHORCFFOSRBP-UHFFFAOYSA-N 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 4
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- BSRDNMMLQYNQQD-UHFFFAOYSA-N iminodiacetonitrile Chemical compound N#CCNCC#N BSRDNMMLQYNQQD-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 3
- HLSQNFKLVXLSRS-QMMMGPOBSA-N (2s)-3-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2-methylpropan-1-ol Chemical compound OC[C@@H](C)CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HLSQNFKLVXLSRS-QMMMGPOBSA-N 0.000 description 3
- DUAXLVGFFDFSAG-YFKPBYRVSA-N (2s)-4-amino-2-methylbutan-1-ol Chemical compound OC[C@@H](C)CCN DUAXLVGFFDFSAG-YFKPBYRVSA-N 0.000 description 3
- XNIOWJUQPMKCIJ-UHFFFAOYSA-N 2-(benzylamino)ethanol Chemical compound OCCNCC1=CC=CC=C1 XNIOWJUQPMKCIJ-UHFFFAOYSA-N 0.000 description 3
- VOTKXBLXKMYHOE-UHFFFAOYSA-N 2-chloro-5-methyl-4-phenylpyridine-3-carboxylic acid Chemical compound CC1=CN=C(Cl)C(C(O)=O)=C1C1=CC=CC=C1 VOTKXBLXKMYHOE-UHFFFAOYSA-N 0.000 description 3
- AJXVJGNSCGWNFP-UHFFFAOYSA-N 2-chloro-6-methyl-4-phenylpyridine-3-carboxylic acid Chemical compound ClC1=NC(C)=CC(C=2C=CC=CC=2)=C1C(O)=O AJXVJGNSCGWNFP-UHFFFAOYSA-N 0.000 description 3
- GGKCSXZFEUHVBM-UHFFFAOYSA-N 3-[[3,5-bis(trifluoromethyl)phenyl]methylamino]propan-1-ol Chemical compound OCCCNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GGKCSXZFEUHVBM-UHFFFAOYSA-N 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229960003071 bacitracin Drugs 0.000 description 3
- 229930184125 bacitracin Natural products 0.000 description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 3
- 150000001555 benzenes Chemical group 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 150000001649 bromium compounds Chemical class 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000010531 catalytic reduction reaction Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 3
- 229910000105 potassium hydride Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000000464 thioxo group Chemical group S=* 0.000 description 3
- FVXBTPGZQMNAEZ-SCSAIBSYSA-N (2r)-3-amino-2-methylpropan-1-ol Chemical compound NC[C@@H](C)CO FVXBTPGZQMNAEZ-SCSAIBSYSA-N 0.000 description 2
- HJARAYMXDYVLBL-JTQLQIEISA-N (2s)-3-(benzylamino)-2-methylpropan-1-ol Chemical compound OC[C@@H](C)CNCC1=CC=CC=C1 HJARAYMXDYVLBL-JTQLQIEISA-N 0.000 description 2
- FVXBTPGZQMNAEZ-BYPYZUCNSA-N (2s)-3-amino-2-methylpropan-1-ol Chemical compound NC[C@H](C)CO FVXBTPGZQMNAEZ-BYPYZUCNSA-N 0.000 description 2
- MXPHPAPKVHWDQO-QGZVFWFLSA-N (9r)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-phenyl-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=CC=C1 MXPHPAPKVHWDQO-QGZVFWFLSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- DUAXLVGFFDFSAG-UHFFFAOYSA-N 4-amino-2-methylbutan-1-ol Chemical compound OCC(C)CCN DUAXLVGFFDFSAG-UHFFFAOYSA-N 0.000 description 2
- SSWNADJOAOFVSB-UHFFFAOYSA-N 5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1=C(C(O)=O)OC(=O)C2=NC=CC=C12 SSWNADJOAOFVSB-UHFFFAOYSA-N 0.000 description 2
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 2
- QXKWSWKQGHRGTD-UHFFFAOYSA-N 5-methyl-4-phenylpyridine-2,3-dicarboxylic acid Chemical compound CC1=CN=C(C(O)=O)C(C(O)=O)=C1C1=CC=CC=C1 QXKWSWKQGHRGTD-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 2
- 102000046798 Neurokinin B Human genes 0.000 description 2
- 101800002813 Neurokinin-B Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZPWKYNJFFAWNSM-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZPWKYNJFFAWNSM-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006251 butylcarbonyl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- CEAJFNBWKBTRQE-UHFFFAOYSA-N methanamine;methanol Chemical compound NC.OC CEAJFNBWKBTRQE-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- AVYCTPIIZIUJRQ-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C1=C(C=2C=CC(C)=CC=2)C2=CC=CN=C2C(=O)O1 AVYCTPIIZIUJRQ-UHFFFAOYSA-N 0.000 description 2
- PCELUFFHSHHQLH-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-(3-chloropropyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCCCl)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PCELUFFHSHHQLH-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000005702 oxyalkylene group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 2
- 108010072906 phosphoramidon Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CAKSQJHKMIOEQW-UHFFFAOYSA-N tert-butyl n-[2-[[3,5-bis(trifluoromethyl)phenyl]methylamino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CAKSQJHKMIOEQW-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HSUHYZSPOPOXGS-JOZHSPBCSA-N (2R)-3-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2-methylpropan-1-ol N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-N-[(2R)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenylpyridine-3-carboxamide Chemical compound FC(C=1C=C(CNC[C@H](CO)C)C=C(C1)C(F)(F)F)(F)F.FC(C=1C=C(CN(C(=O)C=2C(=NC=C(C2C2=CC=CC=C2)C)Cl)C[C@H](CO)C)C=C(C1)C(F)(F)F)(F)F HSUHYZSPOPOXGS-JOZHSPBCSA-N 0.000 description 1
- HJARAYMXDYVLBL-SNVBAGLBSA-N (2r)-3-(benzylamino)-2-methylpropan-1-ol Chemical compound OC[C@H](C)CNCC1=CC=CC=C1 HJARAYMXDYVLBL-SNVBAGLBSA-N 0.000 description 1
- HLSQNFKLVXLSRS-MRVPVSSYSA-N (2r)-3-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2-methylpropan-1-ol Chemical compound OC[C@H](C)CNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HLSQNFKLVXLSRS-MRVPVSSYSA-N 0.000 description 1
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- YUPUSBMJCFBHAP-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1OC YUPUSBMJCFBHAP-UHFFFAOYSA-N 0.000 description 1
- IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
- YGZJTYCCONJJGZ-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1 YGZJTYCCONJJGZ-UHFFFAOYSA-N 0.000 description 1
- JJIHDHICNDMUCJ-OAHLLOKOSA-N (3r)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3,8-dimethyl-7-phenyl-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C1=2)C)OC1=NC=C(C)C=2C1=CC=CC=C1 JJIHDHICNDMUCJ-OAHLLOKOSA-N 0.000 description 1
- NLHDZIOBAMLXHA-OAHLLOKOSA-N (3r)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-methyl-7-phenyl-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C1=2)C)OC1=NC=CC=2C1=CC=CC=C1 NLHDZIOBAMLXHA-OAHLLOKOSA-N 0.000 description 1
- SEJHVQYNAWQUCH-INIZCTEOSA-N (3s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-methyl-7-(4-methylphenyl)-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C1=2)C)OC1=NC=CC=2C1=CC=C(C)C=C1 SEJHVQYNAWQUCH-INIZCTEOSA-N 0.000 description 1
- NLHDZIOBAMLXHA-HNNXBMFYSA-N (3s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-methyl-7-phenyl-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C1=2)C)OC1=NC=CC=2C1=CC=CC=C1 NLHDZIOBAMLXHA-HNNXBMFYSA-N 0.000 description 1
- NKWIRLNSVXDWMJ-SFHVURJKSA-N (3s)-5-benzyl-3-methyl-7-(4-methylphenyl)-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@H](CN(CC=1C=CC=CC=1)C(=O)C1=2)C)OC1=NC=CC=2C1=CC=C(C)C=C1 NKWIRLNSVXDWMJ-SFHVURJKSA-N 0.000 description 1
- ZHKXTYHDFYLZLZ-KRWDZBQOSA-N (3s)-5-benzyl-3-methyl-7-phenyl-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound C([C@H](CN(CC=1C=CC=CC=1)C(=O)C1=2)C)OC1=NC=CC=2C1=CC=CC=C1 ZHKXTYHDFYLZLZ-KRWDZBQOSA-N 0.000 description 1
- JAXJUENAJXWFBX-YFKPBYRVSA-N (4S)-4-aminopentan-1-ol Chemical compound N[C@H](CCCO)C JAXJUENAJXWFBX-YFKPBYRVSA-N 0.000 description 1
- KQYLKORWMZUXOL-HXUWFJFHSA-N (9r)-7-[(3,5-dimethoxyphenyl)methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound COC1=CC(OC)=CC(CN2C(C=3N(C(C4=NC=CC=C4C=3C=3C=CC(C)=CC=3)=O)CC[C@@H](C)C2)=O)=C1 KQYLKORWMZUXOL-HXUWFJFHSA-N 0.000 description 1
- XSHLMXIETOERIX-HXUWFJFHSA-N (9r)-7-benzyl-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=CC=CC=1)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 XSHLMXIETOERIX-HXUWFJFHSA-N 0.000 description 1
- BNMWVEHNLQSOJC-HXUWFJFHSA-N (9r)-9-methyl-5-(4-methylphenyl)-7-[(3,4,5-trimethoxyphenyl)methyl]-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound COC1=C(OC)C(OC)=CC(CN2C(C=3N(C(C4=NC=CC=C4C=3C=3C=CC(C)=CC=3)=O)CC[C@@H](C)C2)=O)=C1 BNMWVEHNLQSOJC-HXUWFJFHSA-N 0.000 description 1
- XSHLMXIETOERIX-FQEVSTJZSA-N (9s)-7-benzyl-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@@H](CN(CC=1C=CC=CC=1)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 XSHLMXIETOERIX-FQEVSTJZSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ATLQGZVLWOURFU-UHFFFAOYSA-N 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CBr)=CC(C(F)(F)F)=C1 ATLQGZVLWOURFU-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- XUVHCEGOKVEAGV-UHFFFAOYSA-N 2,3,4,8,9,10-hexahydropyrimido[1,2-a]azepine Chemical compound C1CCC=CN2CCCN=C21 XUVHCEGOKVEAGV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MAMWMKSUPWMGOX-UHFFFAOYSA-N 2-[(3,4,5-trimethoxyphenyl)methylamino]ethanol Chemical compound COC1=CC(CNCCO)=CC(OC)=C1OC MAMWMKSUPWMGOX-UHFFFAOYSA-N 0.000 description 1
- VIYIYSBQARQLCC-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)methylamino]ethanol Chemical compound OCCNCC1=CC=C(Cl)C(Cl)=C1 VIYIYSBQARQLCC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YPKREXJMEPPLQX-UHFFFAOYSA-N 2-[6-[[3,5-bis(trifluoromethyl)phenyl]methylcarbamoyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridin-7-yl]ethyl methanesulfonate Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCOS(C)(=O)=O)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YPKREXJMEPPLQX-UHFFFAOYSA-N 0.000 description 1
- YRFRKHQASZDPAV-UHFFFAOYSA-N 2-[6-cyano-5-(4-methylphenyl)-8-oxo-1,7-naphthyridin-7-yl]acetic acid Chemical compound C1=CC(C)=CC=C1C1=C(C#N)N(CC(O)=O)C(=O)C2=NC=CC=C12 YRFRKHQASZDPAV-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CDHSJTFINGTIIQ-UHFFFAOYSA-N 2-chloro-4-(4-methylphenyl)pyridine-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1=CC=NC(Cl)=C1C(O)=O CDHSJTFINGTIIQ-UHFFFAOYSA-N 0.000 description 1
- OCMYCMVJEHRRJQ-UHFFFAOYSA-N 2-chloro-n-(2-hydroxyethyl)-4-phenyl-n-[(3,4,5-trimethoxyphenyl)methyl]pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(CN(CCO)C(=O)C=2C(=CC=NC=2Cl)C=2C=CC=CC=2)=C1 OCMYCMVJEHRRJQ-UHFFFAOYSA-N 0.000 description 1
- QQVHDNHHNQIGAA-UHFFFAOYSA-N 2-chloro-n-(3-hydroxypropyl)-4-phenyl-n-[(3,4,5-trimethoxyphenyl)methyl]pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(CN(CCCO)C(=O)C=2C(=CC=NC=2Cl)C=2C=CC=CC=2)=C1 QQVHDNHHNQIGAA-UHFFFAOYSA-N 0.000 description 1
- ZJMAPWGPEXQQLX-UHFFFAOYSA-N 2-chloro-n-[(3,4-dichlorophenyl)methyl]-n-(2-hydroxyethyl)-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCO)CC1=CC=C(Cl)C(Cl)=C1 ZJMAPWGPEXQQLX-UHFFFAOYSA-N 0.000 description 1
- WHYAPACCQBOJST-UHFFFAOYSA-N 2-chloro-n-[(3,4-dimethoxyphenyl)methyl]-n-(2-hydroxyethyl)-4-phenylpyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CN(CCO)C(=O)C1=C(Cl)N=CC=C1C1=CC=CC=C1 WHYAPACCQBOJST-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- YWPSPZSSBHAEAK-UHFFFAOYSA-N 3-[(3,4,5-trimethoxyphenyl)methylamino]propan-1-ol Chemical compound COC1=CC(CNCCCO)=CC(OC)=C1OC YWPSPZSSBHAEAK-UHFFFAOYSA-N 0.000 description 1
- AGMZSYQMSHMXLT-UHFFFAOYSA-N 3-aminobutan-1-ol Chemical compound CC(N)CCO AGMZSYQMSHMXLT-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- YERHKEWRHQIXFY-UHFFFAOYSA-N 3-benzoylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=C1C(=O)C1=CC=CC=C1 YERHKEWRHQIXFY-UHFFFAOYSA-N 0.000 description 1
- PQIYSSSTRHVOBW-UHFFFAOYSA-N 3-bromopropan-1-amine;hydron;bromide Chemical compound Br.NCCCBr PQIYSSSTRHVOBW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- NWKVRFHLBBZSMR-UHFFFAOYSA-N 3-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-n-ethyl-3-n-(2-hydroxyethyl)-5-methyl-4-phenylpyridine-2,3-dicarboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(C(=O)NCC)=NC=C(C)C=1C1=CC=CC=C1 NWKVRFHLBBZSMR-UHFFFAOYSA-N 0.000 description 1
- MTGJSOVYAQVSJL-UHFFFAOYSA-N 3-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-n-(2-hydroxyethyl)-2-n,5-dimethyl-4-phenylpyridine-2,3-dicarboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(C(=O)NC)=NC=C(C)C=1C1=CC=CC=C1 MTGJSOVYAQVSJL-UHFFFAOYSA-N 0.000 description 1
- UHYIHKMIYIPACY-UHFFFAOYSA-N 3-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-n-(2-hydroxyethyl)-2-n-methyl-4-phenylpyridine-2,3-dicarboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(C(=O)NC)=NC=CC=1C1=CC=CC=C1 UHYIHKMIYIPACY-UHFFFAOYSA-N 0.000 description 1
- FHPRCFZACXNRGM-UHFFFAOYSA-N 3-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3-n-(3-hydroxypropyl)-2-n,5-dimethyl-4-phenylpyridine-2,3-dicarboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCCO)C(=O)C=1C(C(=O)NC)=NC=C(C)C=1C1=CC=CC=C1 FHPRCFZACXNRGM-UHFFFAOYSA-N 0.000 description 1
- SHBONSMNWLLFIU-UHFFFAOYSA-N 3-n-benzyl-3-n-(2-hydroxyethyl)-2-n,5-dimethyl-4-phenylpyridine-2,3-dicarboxamide Chemical compound C=1C=CC=CC=1CN(CCO)C(=O)C=1C(C(=O)NC)=NC=C(C)C=1C1=CC=CC=C1 SHBONSMNWLLFIU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RWLMQBFRSUZBTJ-UHFFFAOYSA-N 4-(4-methylbenzoyl)pyridine-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=NC=C1C(O)=O RWLMQBFRSUZBTJ-UHFFFAOYSA-N 0.000 description 1
- MCOVQTGGBQICHH-UHFFFAOYSA-N 4-(4-methylphenyl)-1-oxopyrano[3,4-c]pyridine-3-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1=C(C(O)=O)OC(=O)C2=CN=CC=C12 MCOVQTGGBQICHH-UHFFFAOYSA-N 0.000 description 1
- ZIZPZNAZUUZISD-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound C1=C(OC)C(OC)=CC=C1CN1C(=O)C2=C(C=3C=CC=CC=3)C=CN=C2OCC1 ZIZPZNAZUUZISD-UHFFFAOYSA-N 0.000 description 1
- DVERXRKWMQYHAV-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-8-carboxamide Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(C(=O)N)=CC=2C1=CC=CC=C1 DVERXRKWMQYHAV-UHFFFAOYSA-N 0.000 description 1
- UOWLBSPBQYYFCK-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-(4-methylphenyl)-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound C1=CC(C)=CC=C1C1=CC=NC2=C1C(=O)N(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)CCO2 UOWLBSPBQYYFCK-UHFFFAOYSA-N 0.000 description 1
- GQGQYQRPULMLTJ-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-phenyl-2,3-dihydro-1h-pyrido[2,3-e][1,4]diazepin-5-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C3=C(C=4C=CC=CC=4)C=CN=C3NCC2)=O)=C1 GQGQYQRPULMLTJ-UHFFFAOYSA-N 0.000 description 1
- XCBWMEKXEMHYJM-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C3=C(C=4C=CC=CC=4)C=CN=C3OCC2)=O)=C1 XCBWMEKXEMHYJM-UHFFFAOYSA-N 0.000 description 1
- MLCAUFVIKAJZHS-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-(methoxymethyl)-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(COC)=CC=2C1=CC=CC=C1 MLCAUFVIKAJZHS-UHFFFAOYSA-N 0.000 description 1
- OUUDZAJYPJAJBB-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-(methylaminomethyl)-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(CNC)=CC=2C1=CC=CC=C1 OUUDZAJYPJAJBB-UHFFFAOYSA-N 0.000 description 1
- PIZSJZZTMBKWNU-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-[(4-methylpiperazin-1-yl)methyl]-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound C1CN(C)CCN1CC1=CC(C=2C=CC=CC=2)=C2C(=O)N(CC=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)CCOC2=N1 PIZSJZZTMBKWNU-UHFFFAOYSA-N 0.000 description 1
- UTUFBOQJWZRYDN-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n,n-dimethyl-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-8-carboxamide Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(C(=O)N(C)C)=CC=2C1=CC=CC=C1 UTUFBOQJWZRYDN-UHFFFAOYSA-N 0.000 description 1
- JBNYOQBHCDNYSD-UHFFFAOYSA-N 4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-butyl-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-8-carboxamide Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(C(=O)NCCCC)=CC=2C1=CC=CC=C1 JBNYOQBHCDNYSD-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- JZAIYKGLGWZYSL-UHFFFAOYSA-N 4-benzyl-6-(4-methylphenyl)-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound C1=CC(C)=CC=C1C1=CC=NC2=C1C(=O)N(CC=1C=CC=CC=1)CCO2 JZAIYKGLGWZYSL-UHFFFAOYSA-N 0.000 description 1
- NXFNZNYAAIDLFV-UHFFFAOYSA-N 4-benzyl-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound C1COC2=NC=CC(C=3C=CC=CC=3)=C2C(=O)N1CC1=CC=CC=C1 NXFNZNYAAIDLFV-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- WHGQDTVMWHKFSF-UHFFFAOYSA-N 4-phenylpyridine-2,3-dicarboxylic acid Chemical compound OC(=O)C1=NC=CC(C=2C=CC=CC=2)=C1C(O)=O WHGQDTVMWHKFSF-UHFFFAOYSA-N 0.000 description 1
- ZAMQXZNYNCFWIK-UHFFFAOYSA-N 5-(4-methylphenyl)-8,9-dihydro-[1,4]oxazino[3,4-g][1,7]naphthyridine-6,11-dione Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C1=O)=C2N1CCOC2=O ZAMQXZNYNCFWIK-UHFFFAOYSA-N 0.000 description 1
- MKAKYDRLETXACD-UHFFFAOYSA-N 5-(4-methylphenyl)-8-oxo-n-[(3,4,5-trimethoxyphenyl)methyl]pyrano[3,4-b]pyridine-6-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(CNC(=O)C2=C(C3=CC=CN=C3C(=O)O2)C=2C=CC(C)=CC=2)=C1 MKAKYDRLETXACD-UHFFFAOYSA-N 0.000 description 1
- PHXHLKKOMBBLQE-UHFFFAOYSA-N 5-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-methyl-7-phenyl-3,4-dihydro-2h-pyrido[2,3-b][1,5]oxazocin-6-one Chemical compound O=C1C2=C(C=3C=CC=CC=3)C(C)=CN=C2OCCCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PHXHLKKOMBBLQE-UHFFFAOYSA-N 0.000 description 1
- PDNKUUUATFHLAS-UHFFFAOYSA-N 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3,10-dimethyl-4-phenyl-8,9-dihydro-7h-pyrido[2,3-g][1,5]diazonine-5,11-dione Chemical compound O=C1C(C(=C(C)C=N2)C=3C=CC=CC=3)=C2C(=O)N(C)CCCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PDNKUUUATFHLAS-UHFFFAOYSA-N 0.000 description 1
- KQKSQXKOJAMHST-UHFFFAOYSA-N 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-3,9-dimethyl-4-phenyl-7,8-dihydropyrido[2,3-f][1,4]diazocine-5,10-dione Chemical compound O=C1C(C(=C(C)C=N2)C=3C=CC=CC=3)=C2C(=O)N(C)CCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KQKSQXKOJAMHST-UHFFFAOYSA-N 0.000 description 1
- QIYIVMVXBIUESQ-UHFFFAOYSA-N 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-ethyl-3-methyl-4-phenyl-7,8-dihydropyrido[2,3-f][1,4]diazocine-5,10-dione Chemical compound O=C1C(C(=C(C)C=N2)C=3C=CC=CC=3)=C2C(=O)N(CC)CCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QIYIVMVXBIUESQ-UHFFFAOYSA-N 0.000 description 1
- UEVKGHFSQGBEIM-UHFFFAOYSA-N 6-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-4-phenyl-7,8-dihydropyrido[2,3-f][1,4]diazocine-5,10-dione Chemical compound O=C1C2=C(C=3C=CC=CC=3)C=CN=C2C(=O)N(C)CCN1CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UEVKGHFSQGBEIM-UHFFFAOYSA-N 0.000 description 1
- AUORMMOJOJFHPH-UHFFFAOYSA-N 6-benzyl-3,9-dimethyl-4-phenyl-7,8-dihydropyrido[2,3-f][1,4]diazocine-5,10-dione Chemical compound O=C1C(C(=C(C)C=N2)C=3C=CC=CC=3)=C2C(=O)N(C)CCN1CC1=CC=CC=C1 AUORMMOJOJFHPH-UHFFFAOYSA-N 0.000 description 1
- PXKDHRXMXGNSEE-UHFFFAOYSA-N 6-phenyl-4-[(3,4,5-trimethoxyphenyl)methyl]-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound COC1=C(OC)C(OC)=CC(CN2C(C3=C(C=4C=CC=CC=4)C=CN=C3OCC2)=O)=C1 PXKDHRXMXGNSEE-UHFFFAOYSA-N 0.000 description 1
- YJOFWUMYCWGGTO-UHFFFAOYSA-N 7-(3-bromopropyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1=C(C(O)=O)N(CCCBr)C(=O)C2=NC=CC=C12 YJOFWUMYCWGGTO-UHFFFAOYSA-N 0.000 description 1
- BLCFMRVBNOPAPG-UHFFFAOYSA-N 7-(3-hydroxypropyl)-n-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C(N(C(=O)C1=NC=CC=C11)CCCO)=C1C1=CC=C(C)C=C1 BLCFMRVBNOPAPG-UHFFFAOYSA-N 0.000 description 1
- XBJJVLRTRDPAHO-UHFFFAOYSA-N 7-(4-hydroxybutyl)-n-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C(N(C(=O)C1=NC=CC=C11)CCCCO)=C1C1=CC=C(C)C=C1 XBJJVLRTRDPAHO-UHFFFAOYSA-N 0.000 description 1
- WQDIOQLKWIQGKV-UHFFFAOYSA-N 7-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound COC1=CC=CC=C1CN(CCCCN1C(C2=NC=CC=C22)=O)C(=O)C1=C2C1=CC=C(C)C=C1 WQDIOQLKWIQGKV-UHFFFAOYSA-N 0.000 description 1
- GAYRQSDEDQKXDG-UHFFFAOYSA-N 7-[(2-methoxyphenyl)methyl]-5-(4-methylphenyl)-9,10-dihydro-8h-[1,4]diazepino[2,1-g][1,7]naphthyridine-6,12-dione Chemical compound COC1=CC=CC=C1CN(CCCN1C(C2=NC=CC=C22)=O)C(=O)C1=C2C1=CC=C(C)C=C1 GAYRQSDEDQKXDG-UHFFFAOYSA-N 0.000 description 1
- LZGHRJMNBZMYJC-UHFFFAOYSA-N 7-[(3,4-dichlorophenyl)methyl]-5-phenyl-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C1=C(Cl)C(Cl)=CC=C1CN(CCCCN1C(C2=NC=CC=C22)=O)C(=O)C1=C2C1=CC=CC=C1 LZGHRJMNBZMYJC-UHFFFAOYSA-N 0.000 description 1
- BNZPUTKYXDUHGN-UHFFFAOYSA-N 7-[(3,4-dichlorophenyl)methyl]-5-phenyl-9,10-dihydro-8h-[1,4]diazepino[2,1-g][1,7]naphthyridine-6,12-dione Chemical compound C1=C(Cl)C(Cl)=CC=C1CN(CCCN1C(C2=NC=CC=C22)=O)C(=O)C1=C2C1=CC=CC=C1 BNZPUTKYXDUHGN-UHFFFAOYSA-N 0.000 description 1
- KGJDZILOMKJCBZ-FQEVSTJZSA-N 7-[(3s)-4-hydroxy-3-methylbutyl]-5-(4-methylphenyl)-8-oxo-n-[(3,4,5-trimethoxyphenyl)methyl]-1,7-naphthyridine-6-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(CNC(=O)C=2N(C(=O)C3=NC=CC=C3C=2C=2C=CC(C)=CC=2)CC[C@H](C)CO)=C1 KGJDZILOMKJCBZ-FQEVSTJZSA-N 0.000 description 1
- UUFIVHGGWFGKRM-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-phenyl-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C=3N(C(C4=NC=CC=C4C=3C=3C=CC=CC=3)=O)CCCC2)=O)=C1 UUFIVHGGWFGKRM-UHFFFAOYSA-N 0.000 description 1
- MAGKUSLYBSFJHU-UHFFFAOYSA-N 7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-phenyl-9,10-dihydro-8h-[1,4]diazepino[2,1-g][1,7]naphthyridine-6,12-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(C=3N(C(C4=NC=CC=C4C=3C=3C=CC=CC=3)=O)CCC2)=O)=C1 MAGKUSLYBSFJHU-UHFFFAOYSA-N 0.000 description 1
- IFOPYYTVSNXHPL-UHFFFAOYSA-N 7-benzyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C1=O)=C2N1CCCCN(CC=1C=CC=CC=1)C2=O IFOPYYTVSNXHPL-UHFFFAOYSA-N 0.000 description 1
- IYARRXVZIWNMRT-UHFFFAOYSA-N 7-benzyl-5-phenyl-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C1CCCN(C(C2=NC=CC=C2C=2C=3C=CC=CC=3)=O)C=2C(=O)N1CC1=CC=CC=C1 IYARRXVZIWNMRT-UHFFFAOYSA-N 0.000 description 1
- ASONASPUZYELBH-UHFFFAOYSA-N 8-(aminomethyl)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(CN)=CC=2C1=CC=CC=C1 ASONASPUZYELBH-UHFFFAOYSA-N 0.000 description 1
- COEBACSLKSKMQK-UHFFFAOYSA-N 8-oxo-5-phenylpyrano[3,4-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C=1OC(=O)C2=NC=CC=C2C=1C1=CC=CC=C1 COEBACSLKSKMQK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZTJXPCKPYPAKNT-UHFFFAOYSA-N [1,4]diazepino[2,1-g][1,7]naphthyridine Chemical compound N1=CC=CN2C=C(N=CC=C3)C3=CC2=C1 ZTJXPCKPYPAKNT-UHFFFAOYSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- BSLLUCHMLGPZKQ-UHFFFAOYSA-N [Li].[B].N#C Chemical compound [Li].[B].N#C BSLLUCHMLGPZKQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- UFKDESIUZHMUGL-UHFFFAOYSA-N boron;formonitrile;sodium Chemical compound [B].[Na].N#C UFKDESIUZHMUGL-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 1
- VXZQTXSCMRPKMH-UHFFFAOYSA-N diethyl 2-hydroxypropanedioate Chemical compound CCOC(=O)C(O)C(=O)OCC VXZQTXSCMRPKMH-UHFFFAOYSA-N 0.000 description 1
- GBJMDAQGGISCEE-UHFFFAOYSA-N diethyl 4-hydroxy-4-(4-methylphenyl)-1-oxopyrano[3,4-c]pyridine-3,3-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)OC(=O)C2=CN=CC=C2C1(O)C1=CC=C(C)C=C1 GBJMDAQGGISCEE-UHFFFAOYSA-N 0.000 description 1
- AIGSXBNWAQGDJE-UHFFFAOYSA-N diethyl 4-phenylpyridine-2,3-dicarboxylate Chemical compound CCOC(=O)C1=NC=CC(C=2C=CC=CC=2)=C1C(=O)OCC AIGSXBNWAQGDJE-UHFFFAOYSA-N 0.000 description 1
- LSGXSUCAOFNLEI-UHFFFAOYSA-N diethyl 5-hydroxy-5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6,6-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)OC(=O)C2=NC=CC=C2C1(O)C1=CC=C(C)C=C1 LSGXSUCAOFNLEI-UHFFFAOYSA-N 0.000 description 1
- ZQXOSVIEKSKVCL-UHFFFAOYSA-N diethyl 5-hydroxy-8-oxo-5-phenylpyrano[3,4-b]pyridine-6,6-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)OC(=O)C2=NC=CC=C2C1(O)C1=CC=CC=C1 ZQXOSVIEKSKVCL-UHFFFAOYSA-N 0.000 description 1
- VNFICDJAVJVNKE-UHFFFAOYSA-N diethyl 5-methyl-4-phenylpyridine-2,3-dicarboxylate Chemical compound CCOC(=O)C1=NC=C(C)C(C=2C=CC=CC=2)=C1C(=O)OCC VNFICDJAVJVNKE-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000005949 ethanesulfonyloxy group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- PYXNYPMVFQHNEM-UHFFFAOYSA-N ethyl 2-chloro-6-methyl-4-phenylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=C(Cl)N=C(C)C=C1C1=CC=CC=C1 PYXNYPMVFQHNEM-UHFFFAOYSA-N 0.000 description 1
- PVXGBKMBPOWQHW-UHFFFAOYSA-N ethyl 3-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-hydroxyethyl)carbamoyl]-4-phenylpyridine-2-carboxylate Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(C(=O)OCC)=NC=CC=1C1=CC=CC=C1 PVXGBKMBPOWQHW-UHFFFAOYSA-N 0.000 description 1
- ASRABOKAKYQXLH-UHFFFAOYSA-N ethyl 3-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-hydroxyethyl)carbamoyl]-5-methyl-4-phenylpyridine-2-carboxylate Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(C(=O)OCC)=NC=C(C)C=1C1=CC=CC=C1 ASRABOKAKYQXLH-UHFFFAOYSA-N 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- MCQOWYALZVKMAR-UHFFFAOYSA-N furo[3,4-b]pyridine-5,7-dione Chemical compound C1=CC=C2C(=O)OC(=O)C2=N1 MCQOWYALZVKMAR-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- XHXXWWGGXFUMAJ-UHFFFAOYSA-N methanethiol;sodium Chemical compound [Na].SC XHXXWWGGXFUMAJ-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- BOPDOJLGJPRXLA-UHFFFAOYSA-N n'-[[3,5-bis(trifluoromethyl)phenyl]methyl]ethane-1,2-diamine Chemical compound NCCNCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BOPDOJLGJPRXLA-UHFFFAOYSA-N 0.000 description 1
- BAPYVOBOVVROGQ-UHFFFAOYSA-N n,n-bis(cyanomethyl)-3-(4-methylbenzoyl)pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=CN=C1C(=O)N(CC#N)CC#N BAPYVOBOVVROGQ-UHFFFAOYSA-N 0.000 description 1
- MXSHBTNFPIGKHX-UHFFFAOYSA-N n-(2-aminoethyl)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCN)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MXSHBTNFPIGKHX-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- MHFXFYHADNCGMQ-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-7-(3-hydroxypropyl)-8-oxo-5-phenyl-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=CC=CC=1C=1C2=CC=CN=C2C(=O)N(CCCO)C=1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 MHFXFYHADNCGMQ-UHFFFAOYSA-N 0.000 description 1
- DTQZKVUHMLODOC-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-8-oxo-5-phenylpyrano[3,4-b]pyridine-6-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(=O)C1=C(C=2C=CC=CC=2)C2=CC=CN=C2C(=O)O1 DTQZKVUHMLODOC-UHFFFAOYSA-N 0.000 description 1
- FQKJEFSOIHKJQQ-UHFFFAOYSA-N n-[(3,5-dimethoxyphenyl)methyl]-5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxamide Chemical compound COC1=CC(OC)=CC(CNC(=O)C2=C(C3=CC=CN=C3C(=O)O2)C=2C=CC(C)=CC=2)=C1 FQKJEFSOIHKJQQ-UHFFFAOYSA-N 0.000 description 1
- OMXLFWQRFCOOTB-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-hydroxybutyl)-4-(4-methylphenyl)-1-oxo-2,7-naphthyridine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=NC=C1C(=O)N1CCCCO)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OMXLFWQRFCOOTB-UHFFFAOYSA-N 0.000 description 1
- ZVVXELOOZZJVPT-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(2-hydroxyethyl)-4-(4-methylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C1=CC=NC(Cl)=C1C(=O)N(CCO)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZVVXELOOZZJVPT-UHFFFAOYSA-N 0.000 description 1
- OGKJPXRESICEPO-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(2-hydroxyethyl)-5-methyl-4-phenylpyridine-3-carboxamide Chemical compound C=1C=CC=CC=1C=1C(C)=CN=C(Cl)C=1C(=O)N(CCO)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OGKJPXRESICEPO-UHFFFAOYSA-N 0.000 description 1
- OKMFGLHNMGNBKO-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(2-hydroxyethyl)-6-methyl-4-phenylpyridine-3-carboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCO)C(=O)C=1C(Cl)=NC(C)=CC=1C1=CC=CC=C1 OKMFGLHNMGNBKO-UHFFFAOYSA-N 0.000 description 1
- QHGPDKZJLQHHMU-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(3-hydroxypropyl)-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCCO)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QHGPDKZJLQHHMU-UHFFFAOYSA-N 0.000 description 1
- UXBKUNBQQKVDEJ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(3-hydroxypropyl)-5-methyl-4-phenylpyridine-3-carboxamide Chemical compound C=1C=CC=CC=1C=1C(C)=CN=C(Cl)C=1C(=O)N(CCCO)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UXBKUNBQQKVDEJ-UHFFFAOYSA-N 0.000 description 1
- SRTFHTSSAVAMNC-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-(3-hydroxypropyl)-6-methyl-4-phenylpyridine-3-carboxamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1CN(CCCO)C(=O)C=1C(Cl)=NC(C)=CC=1C1=CC=CC=C1 SRTFHTSSAVAMNC-UHFFFAOYSA-N 0.000 description 1
- CZCGLVSRNZKKKH-OAHLLOKOSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-[(2r)-3-hydroxy-2-methylpropyl]-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C[C@H](CO)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CZCGLVSRNZKKKH-OAHLLOKOSA-N 0.000 description 1
- WSZZBEOLQZJLRB-INIZCTEOSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-[(2s)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)pyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC(C)=CC=2)C=1C(=O)N(C[C@@H](CO)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WSZZBEOLQZJLRB-INIZCTEOSA-N 0.000 description 1
- CZCGLVSRNZKKKH-HNNXBMFYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-[(2s)-3-hydroxy-2-methylpropyl]-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C[C@@H](CO)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CZCGLVSRNZKKKH-HNNXBMFYSA-N 0.000 description 1
- QUADTYYKGMNFIH-HNNXBMFYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-chloro-n-[(2s)-3-hydroxy-2-methylpropyl]-5-methyl-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC(C)=C(C=2C=CC=CC=2)C=1C(=O)N(C[C@@H](CO)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QUADTYYKGMNFIH-HNNXBMFYSA-N 0.000 description 1
- WZJPALMNUHKHRA-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C1=C(C(=O)NCC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)OC(=O)C2=NC=CC=C12 WZJPALMNUHKHRA-UHFFFAOYSA-N 0.000 description 1
- BTTVQYXJTZUNJJ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-(2-hydroxyethyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCO)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BTTVQYXJTZUNJJ-UHFFFAOYSA-N 0.000 description 1
- BAPSVJVDWCPDCW-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-(4-hydroxybutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCCCO)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BAPSVJVDWCPDCW-UHFFFAOYSA-N 0.000 description 1
- ONQZVONNVFAQDJ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-(4-hydroxybutyl)-8-oxo-5-phenyl-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=CC=CC=1C=1C2=CC=CN=C2C(=O)N(CCCCO)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ONQZVONNVFAQDJ-UHFFFAOYSA-N 0.000 description 1
- TWAYKKJWDBBFMJ-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-(5-hydroxypentyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCCCCO)=C1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 TWAYKKJWDBBFMJ-UHFFFAOYSA-N 0.000 description 1
- DMEKZPCOMSAWLW-QGZVFWFLSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-[(2r)-3-hydroxy-2-methylpropyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(C[C@H](CO)C)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DMEKZPCOMSAWLW-QGZVFWFLSA-N 0.000 description 1
- DMEKZPCOMSAWLW-KRWDZBQOSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-[(2s)-3-hydroxy-2-methylpropyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(C[C@@H](CO)C)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DMEKZPCOMSAWLW-KRWDZBQOSA-N 0.000 description 1
- MCASYYBQQDPIPC-GOSISDBHSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-[(3r)-4-hydroxy-3-methylbutyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(CC[C@H](CO)C)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MCASYYBQQDPIPC-GOSISDBHSA-N 0.000 description 1
- MCASYYBQQDPIPC-SFHVURJKSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-[(3s)-4-hydroxy-3-methylbutyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(CC[C@@H](CO)C)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MCASYYBQQDPIPC-SFHVURJKSA-N 0.000 description 1
- WVFAJYUNDVNNHK-KRWDZBQOSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-[(3s)-4-hydroxy-3-methylbutyl]-8-oxo-5-phenyl-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=CC=CC=1C=1C2=CC=CN=C2C(=O)N(CC[C@@H](CO)C)C=1C(=O)NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WVFAJYUNDVNNHK-KRWDZBQOSA-N 0.000 description 1
- MTXGLGPFQGKRFD-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-8-oxo-5-phenylpyrano[3,4-b]pyridine-6-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CNC(=O)C2=C(C3=CC=CN=C3C(=O)O2)C=2C=CC=CC=2)=C1 MTXGLGPFQGKRFD-UHFFFAOYSA-N 0.000 description 1
- UZMQDEFBYKKLMZ-UHFFFAOYSA-N n-[[4-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-oxo-6-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-8-yl]methyl]methanesulfonamide Chemical compound O1CCN(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(=O)C=2C1=NC(CNS(=O)(=O)C)=CC=2C1=CC=CC=C1 UZMQDEFBYKKLMZ-UHFFFAOYSA-N 0.000 description 1
- HUXCPUWDHSZVJC-UHFFFAOYSA-N n-benzyl-2-chloro-n-(2-hydroxyethyl)-4-(4-methylphenyl)pyridine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C1=CC=NC(Cl)=C1C(=O)N(CCO)CC1=CC=CC=C1 HUXCPUWDHSZVJC-UHFFFAOYSA-N 0.000 description 1
- XBPHINFGKHPNNA-UHFFFAOYSA-N n-benzyl-2-chloro-n-(2-hydroxyethyl)-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCO)CC1=CC=CC=C1 XBPHINFGKHPNNA-UHFFFAOYSA-N 0.000 description 1
- DRWVAAYTWMQSRQ-QGZVFWFLSA-N n-benzyl-2-chloro-n-[(2r)-3-hydroxy-2-methylpropyl]-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C[C@H](CO)C)CC1=CC=CC=C1 DRWVAAYTWMQSRQ-QGZVFWFLSA-N 0.000 description 1
- WTJSSIKIMPENAL-SFHVURJKSA-N n-benzyl-2-chloro-n-[(2s)-3-hydroxy-2-methylpropyl]-4-(4-methylphenyl)pyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC(C)=CC=2)C=1C(=O)N(C[C@@H](CO)C)CC1=CC=CC=C1 WTJSSIKIMPENAL-SFHVURJKSA-N 0.000 description 1
- DRWVAAYTWMQSRQ-KRWDZBQOSA-N n-benzyl-2-chloro-n-[(2s)-3-hydroxy-2-methylpropyl]-4-phenylpyridine-3-carboxamide Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C[C@@H](CO)C)CC1=CC=CC=C1 DRWVAAYTWMQSRQ-KRWDZBQOSA-N 0.000 description 1
- LWXZUYZSWFHJKB-UHFFFAOYSA-N n-benzyl-5-(4-methylphenyl)-8-oxopyrano[3,4-b]pyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C1=C(C(=O)NCC=2C=CC=CC=2)OC(=O)C2=NC=CC=C12 LWXZUYZSWFHJKB-UHFFFAOYSA-N 0.000 description 1
- CURMQUJNVDNXKW-UHFFFAOYSA-N n-benzyl-7-(4-hydroxybutyl)-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(C1=CC=CN=C1C(=O)N1CCCCO)=C1C(=O)NCC1=CC=CC=C1 CURMQUJNVDNXKW-UHFFFAOYSA-N 0.000 description 1
- KTHMUJCOPKHCPH-HXUWFJFHSA-N n-benzyl-7-[(3r)-4-hydroxy-3-methylbutyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(CC[C@H](CO)C)C=1C(=O)NCC1=CC=CC=C1 KTHMUJCOPKHCPH-HXUWFJFHSA-N 0.000 description 1
- KTHMUJCOPKHCPH-FQEVSTJZSA-N n-benzyl-7-[(3s)-4-hydroxy-3-methylbutyl]-5-(4-methylphenyl)-8-oxo-1,7-naphthyridine-6-carboxamide Chemical compound C=1C=C(C)C=CC=1C=1C2=CC=CN=C2C(=O)N(CC[C@@H](CO)C)C=1C(=O)NCC1=CC=CC=C1 KTHMUJCOPKHCPH-FQEVSTJZSA-N 0.000 description 1
- SDVFRMKWVAHMJA-UHFFFAOYSA-N n-benzyl-8-oxo-5-phenylpyrano[3,4-b]pyridine-6-carboxamide Chemical compound O1C(=O)C2=NC=CC=C2C(C=2C=CC=CC=2)=C1C(=O)NCC1=CC=CC=C1 SDVFRMKWVAHMJA-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- HBEQXAKJSGXAIQ-UHFFFAOYSA-N oxopalladium Chemical compound [Pd]=O HBEQXAKJSGXAIQ-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- BHZSLLSDZFAPFH-UHFFFAOYSA-L palladium(2+);difluoride Chemical compound F[Pd]F BHZSLLSDZFAPFH-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002248 primary sensory neuron Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003900 secondary neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- YCPWVSBDHQSWQL-UHFFFAOYSA-N tert-butyl n-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-chloro-4-phenylpyridine-3-carbonyl)amino]ethyl]carbamate Chemical compound ClC=1N=CC=C(C=2C=CC=CC=2)C=1C(=O)N(CCNC(=O)OC(C)(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YCPWVSBDHQSWQL-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 1
- 239000012000 urushibara nickel Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9143695 | 1995-03-24 | ||
JP20755395 | 1995-07-20 | ||
JP26472795 | 1995-09-18 | ||
JP3003396 | 1996-01-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO961160D0 NO961160D0 (no) | 1996-03-21 |
NO961160L NO961160L (no) | 1996-09-25 |
NO309272B1 true NO309272B1 (no) | 2001-01-08 |
Family
ID=27459171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO961160A NO309272B1 (no) | 1995-03-24 | 1996-03-21 | Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene |
Country Status (17)
Country | Link |
---|---|
US (3) | US5786352A (es) |
EP (1) | EP0733632B1 (es) |
KR (1) | KR960034203A (es) |
CN (1) | CN1140172A (es) |
AR (1) | AR003937A1 (es) |
AT (1) | ATE242243T1 (es) |
AU (1) | AU699611B2 (es) |
BR (1) | BR9601125A (es) |
CA (1) | CA2172421A1 (es) |
DE (1) | DE69628484T2 (es) |
ES (1) | ES2194937T3 (es) |
HU (1) | HUP9600732A3 (es) |
IL (1) | IL117631A (es) |
MX (1) | MX9601072A (es) |
NO (1) | NO309272B1 (es) |
NZ (1) | NZ286256A (es) |
TW (1) | TW394773B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
KR20010041991A (ko) * | 1998-03-19 | 2001-05-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도 |
WO2000012503A1 (fr) * | 1998-08-26 | 2000-03-09 | Tanabe Seiyaku Co., Ltd. | Derives de naphthyridine et leur procede de preparation |
AU1409100A (en) * | 1998-11-27 | 2000-06-19 | Takeda Chemical Industries Ltd. | Drugs |
CZ20013047A3 (cs) * | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | 3-Fenylpyridinové deriváty a jejich pouľití jako antagonisty NK-1 receptorů |
ES2226622T3 (es) | 1999-02-24 | 2005-04-01 | F. Hoffmann-La Roche Ag | Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1. |
RU2309953C2 (ru) | 1999-11-03 | 2007-11-10 | Эймр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе |
US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
TR200302077T4 (tr) * | 1999-11-29 | 2004-01-21 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit |
KR100821410B1 (ko) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도 |
CA2423364A1 (en) * | 2000-09-26 | 2003-03-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for emotional disorders |
EP1352659A4 (en) * | 2000-12-22 | 2004-06-30 | Takeda Chemical Industries Ltd | COMBINATION DRUGS |
MXPA03010612A (es) | 2001-05-22 | 2004-04-02 | Neurogen Corp | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. |
WO2003029254A1 (fr) * | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Procede de preparation de composes tricycliques |
EP1457493A4 (en) * | 2001-12-10 | 2005-11-30 | Kyorin Seiyaku Kk | CONDENSED, BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS |
US6995153B2 (en) * | 2002-01-18 | 2006-02-07 | Kyorin Pharmaceutical. Co., Ltd. | Fused bicyclic pyrimidine derivatives |
CA2479279A1 (en) * | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceutical Co., Ltd. | Fused bicyclic pyridine derivative as tachykinin receptor antagonist |
US7625887B2 (en) | 2003-01-28 | 2009-12-01 | Takeda Pharmaceutical Company Limited | Receptor agonists |
US7288658B2 (en) | 2003-07-15 | 2007-10-30 | Hoffmann-La Roche Inc. | Process for preparation of pyridine derivatives |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
MY143784A (en) | 2005-09-23 | 2011-07-15 | Hoffmann La Roche | Novel dosage formulation |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
JPWO2010016552A1 (ja) | 2008-08-07 | 2012-01-26 | 武田薬品工業株式会社 | 過敏性腸症候群治療薬 |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子1受容体阻害剤 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015116904A1 (en) | 2014-02-03 | 2015-08-06 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
JP6628805B2 (ja) | 2015-02-03 | 2020-01-15 | ファイザー・インク | 新規シクロプロパベンゾフラニルピリドピラジンジオン |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
RU2018121946A (ru) | 2015-11-20 | 2019-12-23 | Вайтаи Фармасьютиклз, Ллк | Модуляторы ror-гамма |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES431307A1 (es) * | 1973-11-16 | 1976-09-01 | Thomae Gmbh Dr K | Procedimiento para la preparacion de nuevos derivados de quinoleina. |
DE2357253A1 (de) * | 1973-11-16 | 1975-05-22 | Thomae Gmbh Dr K | Neue chinolinderivate |
DE2617101A1 (de) * | 1976-04-17 | 1977-11-17 | Thomae Gmbh Dr K | Neue naphthyridine |
DE2638828A1 (de) * | 1976-08-28 | 1978-03-09 | Thomae Gmbh Dr K | Neue thieno-pyridine |
DE2722416A1 (de) * | 1977-05-18 | 1978-11-30 | Thomae Gmbh Dr K | Neue thiazolo-pyridine |
US4746657A (en) * | 1987-07-13 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic tetrahydroazepinones (and thiones) |
TW241258B (es) * | 1992-04-15 | 1995-02-21 | Takeda Pharm Industry Co Ltd | |
US5482967A (en) * | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP0634402A1 (en) * | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
TW263498B (es) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd |
-
1996
- 1996-03-21 TW TW085103427A patent/TW394773B/zh active
- 1996-03-21 ES ES96104500T patent/ES2194937T3/es not_active Expired - Lifetime
- 1996-03-21 DE DE69628484T patent/DE69628484T2/de not_active Expired - Lifetime
- 1996-03-21 EP EP96104500A patent/EP0733632B1/en not_active Expired - Lifetime
- 1996-03-21 NO NO961160A patent/NO309272B1/no not_active IP Right Cessation
- 1996-03-21 AT AT96104500T patent/ATE242243T1/de not_active IP Right Cessation
- 1996-03-22 CA CA002172421A patent/CA2172421A1/en not_active Abandoned
- 1996-03-22 MX MX9601072A patent/MX9601072A/es unknown
- 1996-03-22 HU HU9600732A patent/HUP9600732A3/hu unknown
- 1996-03-22 AR ARP960101863A patent/AR003937A1/es unknown
- 1996-03-22 AU AU48261/96A patent/AU699611B2/en not_active Ceased
- 1996-03-23 CN CN96106081A patent/CN1140172A/zh active Pending
- 1996-03-23 KR KR1019960008047A patent/KR960034203A/ko active IP Right Grant
- 1996-03-24 IL IL11763196A patent/IL117631A/xx not_active IP Right Cessation
- 1996-03-25 US US08/621,360 patent/US5786352A/en not_active Expired - Lifetime
- 1996-03-25 NZ NZ286256A patent/NZ286256A/xx unknown
- 1996-03-25 BR BR9601125A patent/BR9601125A/pt not_active Application Discontinuation
-
1998
- 1998-06-01 US US09/087,894 patent/US6147071A/en not_active Expired - Fee Related
-
2000
- 2000-08-23 US US09/644,306 patent/US6489315B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW394773B (en) | 2000-06-21 |
IL117631A0 (en) | 1996-07-23 |
HUP9600732A2 (en) | 1997-03-28 |
AU4826196A (en) | 1996-10-03 |
AR003937A1 (es) | 1998-09-30 |
US6147071A (en) | 2000-11-14 |
MX9601072A (es) | 1997-03-29 |
NZ286256A (en) | 1999-05-28 |
HU9600732D0 (en) | 1996-05-28 |
US5786352A (en) | 1998-07-28 |
DE69628484T2 (de) | 2004-05-19 |
KR960034203A (ko) | 1996-10-22 |
AU699611B2 (en) | 1998-12-10 |
DE69628484D1 (de) | 2003-07-10 |
ATE242243T1 (de) | 2003-06-15 |
IL117631A (en) | 2000-11-21 |
EP0733632A1 (en) | 1996-09-25 |
ES2194937T3 (es) | 2003-12-01 |
CN1140172A (zh) | 1997-01-15 |
HUP9600732A3 (en) | 2000-03-28 |
BR9601125A (pt) | 1998-01-06 |
NO961160D0 (no) | 1996-03-21 |
US6489315B1 (en) | 2002-12-03 |
EP0733632B1 (en) | 2003-06-04 |
NO961160L (no) | 1996-09-25 |
CA2172421A1 (en) | 1996-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO309272B1 (no) | Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene | |
US5366972A (en) | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | |
CA2558026C (en) | Hiv integrase inhibitors | |
EP0652218B1 (en) | Heterocyclic compounds, their production and use | |
EP0429987B1 (en) | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | |
US5770590A (en) | Cyclic compounds, their prudiction and use | |
KR20070015598A (ko) | 융합 퀴놀린 유도체 및 이의 용도 | |
CA3091486A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
CZ224897A3 (cs) | Tricyklické diazepinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem | |
CZ114593A3 (en) | Imidazopyridine derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
TW201144323A (en) | Amino-oxazines and amino-dihydrothiazine compounds as Beta-secretase modulators and methods of use | |
US20020132817A1 (en) | Heterocyclic compounds, their production and use | |
AU2853299A (en) | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | |
JPH08337583A (ja) | 複素環化合物およびその製造法 | |
NO840068L (no) | Heterocyklisk paakondenserte pyrazolo(3,4-d)pyridin-3-ioner | |
JP2010529143A (ja) | 治療用ピラゾロキノリン誘導体 | |
SK17722002A3 (sk) | Nenukleozidové inhibítory reverznej transkriptázy, farmaceutický prostriedok s ich obsahom a ich použitie | |
EP2736899A1 (en) | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands | |
JP2976097B2 (ja) | 環状化合物、その製造法および剤 | |
JP3993264B2 (ja) | 環状化合物、その製造法および剤 | |
DK170670B1 (da) | Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler | |
JP4738172B2 (ja) | 抗感染薬 | |
NO162188B (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive imidazokinoliner. | |
JPH11322748A (ja) | 複素環化合物、その製造法および用途 | |
JP2007277260A (ja) | 環状化合物、その製造法および剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |